The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Do obese women benefit less from adjuvant endocrine therapy with aromatase inhibitors? Preliminary analysis on the association of BMI and aromatase inhibitor plasma levels.
D. Egle
No relevant relationships to disclose
A. Oberguggenberger
No relevant relationships to disclose
R. Achleitner
No relevant relationships to disclose
M. Sztankay
No relevant relationships to disclose
V. Meraner
No relevant relationships to disclose
J. Giesinger
No relevant relationships to disclose
B. Sperner-Unterweger
No relevant relationships to disclose
B. Holzner
No relevant relationships to disclose
B. Beer
No relevant relationships to disclose
H. Oberacher
No relevant relationships to disclose
C. Marth
No relevant relationships to disclose
M. Hubalek
No relevant relationships to disclose